- Home
- SST vs TVRD Comparison
SST vs TVRD Comparison
Compare SST & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | TVRD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | TVRD |
|---|---|---|
| Price | $4.40 | $4.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $51.67 |
| AVG Volume (30 Days) | 13.3K | ★ 126.7K |
| Earning Date | 03-09-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $3.74 |
| 52 Week High | $15.00 | $43.65 |
Technical Indicators
Market Signals| Indicator | SST | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 44.12 |
| Support Level | $4.09 | $4.39 |
| Resistance Level | $4.60 | $4.89 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 15.27 | 43.63 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.